267 related articles for article (PubMed ID: 28240670)
1. A Rare Case of Omentum Invasive Prostate Cancer: Staging With PSMA PET/CT Imaging and Response to Systemic Therapy.
Ladwa R; Gustafson S; McCaffrey E; Miles K; O'Byrne K
Clin Nucl Med; 2017 Jun; 42(6):e311-e312. PubMed ID: 28240670
[TBL] [Abstract][Full Text] [Related]
2. Abdominal Splenosis Mimicking Peritoneal Metastasis in Prostate-Specific Membrane Antigen PET/CT, Confirmed With Selective Spleen SPECT/CT.
Demirci E; Has Simsek D; Kabasakal L; Mülazimoğlu M
Clin Nucl Med; 2017 Dec; 42(12):e504-e505. PubMed ID: 29076911
[TBL] [Abstract][Full Text] [Related]
3. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
4. Early Detection of Bilateral Testicular Metastases From Prostatic Adenocarcinoma Using 68Ga-PSMA Ligand PET/CT.
Weiberg D; Radner H; Derlin T; Thon WF
Clin Nucl Med; 2017 Jul; 42(7):563-564. PubMed ID: 28368893
[TBL] [Abstract][Full Text] [Related]
5. PSMA PET and Radionuclide Therapy in Prostate Cancer.
Bouchelouche K; Turkbey B; Choyke PL
Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
[TBL] [Abstract][Full Text] [Related]
6. Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria.
Fanti S; Hadaschik B; Herrmann K
J Nucl Med; 2020 May; 61(5):678-682. PubMed ID: 31806774
[TBL] [Abstract][Full Text] [Related]
7. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.
Ceci F; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer.
Ravi Kumar AS; Lawrentschuk N; Hofman MS
Curr Opin Urol; 2020 Sep; 30(5):628-634. PubMed ID: 32701720
[TBL] [Abstract][Full Text] [Related]
9. Bone Infarction Mimicking a Bone Metastasis on 18F-Prostate-Specific Membrane Antigen PET/CT.
Elsobky S; Nathan M; Robertson N; Wagner T
Clin Nucl Med; 2021 May; 46(5):e250-e252. PubMed ID: 33323731
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
Hofman MS; Hicks RJ; Maurer T; Eiber M
Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
[TBL] [Abstract][Full Text] [Related]
11. Therapy assessment in prostate cancer using choline and PSMA PET/CT.
Ceci F; Herrmann K; Hadaschik B; Castellucci P; Fanti S
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):78-83. PubMed ID: 28540419
[TBL] [Abstract][Full Text] [Related]
12. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
[TBL] [Abstract][Full Text] [Related]
13. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
14. The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory.
Sathianathen NJ; Geurts N; Nair R; Lawrentschuk N; Murphy DG; Lamb AD
Future Oncol; 2017 Aug; 13(20):1801-1807. PubMed ID: 28762288
[TBL] [Abstract][Full Text] [Related]
15. Rapidly Evolving Diffuse Omental Carcinomatosis of Prostate Cancer in 68Ga-PSMA PET/CT.
Hoberück S; Sommer U; Grey A; Hölscher T; Baretton GB; Kotzerke J
Clin Nucl Med; 2021 Apr; 46(4):e216-e217. PubMed ID: 33234924
[TBL] [Abstract][Full Text] [Related]
16. Utility of
Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
[TBL] [Abstract][Full Text] [Related]
17. [The role of PSMA PET-CT in patients with metastatic prostate cancer].
von Hardenberg J; Büsing KA; Nuhn P; Ritter M
Urologe A; 2017 Nov; 56(11):1410-1416. PubMed ID: 28980045
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
Kim SJ; Lee SW; Ha HK
Urol Int; 2019; 102(1):27-36. PubMed ID: 30269140
[TBL] [Abstract][Full Text] [Related]
19. PSMA PET/CT for staging and treatment of prostate cancer.
Hofman M
Clin Adv Hematol Oncol; 2019 Jul; 17(7):370-373. PubMed ID: 31449501
[No Abstract] [Full Text] [Related]
20. More than the prostate: Intrapancreatic accessory spleen and papillary thyroid cancer detected with
Singh D; Horneman R; Nagra NK
Hell J Nucl Med; 2018; 21(2):145-147. PubMed ID: 30006647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
